Quantcast

Latest Rosiglitazone Stories

2010-02-24 09:24:00

RESEARCH TRIANGLE PARK, N.C., Feb. 24 /PRNewswire-FirstCall/ -- Today, GlaxoSmithKline (NYSE: GSK) responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report"). To view GSK's response, visit http://www.gsk.com/media/GSK-White-Paper-Avandia-23-Feb-2010.pdf. In its response, GSK states that the Staff Report fails to present an accurate, balanced, or complete view of the currently available...

2010-02-23 15:42:00

DALLAS, Feb. 23 /PRNewswire-USNewswire/ -- The data are inconclusive on heart risks from a class of blood sugar-lowering drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or rosiglitazone (Avandia), but the medications should be used with close monitoring from healthcare providers according to a joint science advisory from the American College of Cardiology and the American Heart Association. The advisory is published online in both Circulation: Journal of the American...

2010-02-11 09:43:07

A Henry Ford Hospital study finds women with type 2 diabetes who take a commonly prescribed class of medications to treat insulin resistance may be at a higher risk for developing bone fractures. After taking a thiazolidinedione (TZD) for one year, women are 50 percent more likely to have a bone fracture than patients not taking TZDs, according to study results. And those at the greatest risk for fractures from TZD use are women older than 65. "Older women are already at a higher risk of...

2010-01-11 06:00:00

LOS ALTOS, Calif., Jan. 11 /PRNewswire/ -- InteKrin Therapeutics Inc. will present at the 28th Annual JP Morgan Global Healthcare Conference at 4:00 p.m. Pacific Time on Monday, January 11, 2010, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference. About InteKrin (www.InteKrin.com): InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company focused on the...

2009-12-04 14:47:58

Research: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database Sulphonylureas, a type of drug widely used to treat type 2 diabetes, carries a greater risk of heart failure and death compared with metformin, another popular antidiabetes drug. The findings, published on bmj.com today, suggest clinically important differences in the cardiovascular...

2009-11-03 10:00:00

NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. GlaxoSmithKline plc: PharmaVitae Profile http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Introduction This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company...

2009-09-29 09:54:30

Research published this week in the open access journal, PLoS Medicine, suggests that there is an association between thiazolidinediones "“ a type of drug introduced in the 1990s to treat type 2 diabetes "“ and bone fracture. Ian Douglas of the London School of Hygiene and Tropical Medicine and colleagues searched the UK General Practice Research Database, a computerized record of clinical records from over 6 million patients registered at 400 general practice surgeries in the...

2009-09-25 04:35:29

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research. And in an animal study, a diabetes drug that promotes insulin sensitivity slowed the progression of muscle wasting and fat loss, the main consequences of a syndrome called cachexia, in mice with colon cancer tumors. Though it remains unknown whether that...

2009-08-25 10:17:49

Canadian scientists say they have discovered rosiglitazone (Avandia) a type 2 diabetes drug, might be linked with increased risk of heart failure and death. The scientists from the University of Toronto and the Sunnybrook Health Sciences Center in Toronto, said the linkage was found among older patients, compared to a similar drug, pioglitazone (Actos). The scientists used prescription records to identify nearly 40,000 patients aged 66 years and older who started treatment with either...

2009-08-20 11:30:48

Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on bmj.com today.As such, the researchers say it is difficult to advocate continued use of rosiglitazone for most patients.Rosiglitazone and pioglitazone belong to a class of drugs called thiazolidinediones and are widely used for the treatment of type 2 diabetes. They help to control...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related